leadf
logo-loader
RNS
viewSkinBioTherapeutics PLC

SkinBioTherapeutics - Appointment of Joint Broker

RNS Number : 0278B
SkinBioTherapeutics PLC
05 January 2018
 

SkinBioTherapeutics plc

 

Appointment of Joint Broker

 

Manchester, UK - 5 January 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, announces the appointment of Northland Capital Partners to act as the Company's Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

-Ends-

 

For more information, please contact:

 

SkinBioTherapeutics plc

Dr. Cath O'Neill, CEO

Doug Quinn, CFO

 

Tel: +44 (0) 161 468 2760

Cairn Financial Advisers LLP (Nominated Advisor)

Tony Rawlinson / Emma Earl / Richard Nash

 

Tel: +44 (0) 20 7213 0880

Turner Pope Investments (Joint Broker)

Ben Turner / James Pope

 

Tel: +44 (0) 20 3621 4120

 

Northland Capital Partners (Joint Broker)

John Howes / Tom Price

 

Tel: +44 (0) 20 3861 6625

 

Instinctif Partners (Media Relations)

Melanie Toyne-Sewell / Deborah Bell

Tel: +44 (0) 20 7457 2020

[email protected]

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBRGDBGGGBGIS

Quick facts: SkinBioTherapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read